NDAINTRAVENOUSSOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
FAMOTIDINE (famotidine) by Sagent Pharmaceuticals is histamine h2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Famotidine is a histamine H2 receptor antagonist administered intravenously as a solution for gastric acid suppression. It works by blocking histamine-2 receptors on parietal cells, reducing gastric acid production. The IV formulation is typically used in acute care settings where oral administration is not feasible.
LAUNCH
Early-stage launch with moderate competitive pressure (30%) indicates active commercial build-out with opportunities for field development and institutional relationships.
Mechanism of Action
Histamine H2 Receptor Antagonists
Pharmacologic Class:
Histamine-2 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
Started Aug 2026
56 enrolled
Healthy Adult Participants
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Started Aug 2025
24 enrolled
Healthy
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
Started Jul 2023
32 enrolled
Healthy Volunteers
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Started Jun 2021
22 enrolled
Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Started Jul 2020
35 enrolled
Healthy Participants
Worked on FAMOTIDINE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.